 Aravive, Inc. ARAV, a clinical-stage biopharmaceutical company, and WuXi Biologics WuXi Bio 2269.HK, a global company with leading open-access biologics technology platforms, today announced a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBodyTM platform to develop high-affinity bispecific antibodies for a target implicated in cancer and fibrosis. Aravive and WuXi Biologics will collaborate to discover antibodies against CCN2, a multidomain protein also known as connective tissue growth factor CTGF. 